RxDoctor Payments Data

Maysaa Basha, MD

Neurology · Detroit, MINPI 1073781571

Payments from drug & device makers

$87,155in general payments, 2019–2025

Across 102 payments — averaging $854.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$46K
  • Sunovion Pharmaceuticals Inc.$36K
  • Pfizer$3K
  • Novartis$446
  • UCB, Inc.$346
  • Neurelis, Inc.$238
  • plus $644 from 9 others

What the payments were for

  • Consulting fees$4,86060%
  • Travel & lodging$94512%
  • Food & beverage$2,11926%
  • Education$1191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,155 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$29,228
Medicare patients
152
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam63$86,347
Oxtellar XrOxcarbazepine42$75,995
OnfiClobazam22$63,801
FycompaPerampanel48$56,527
AptiomEslicarbazepine Acetate25$45,090
XcopriCenobamate19$24,403
NeurontinGabapentin12$17,828
Lacosamide200$16,913
Lamotrigine ErLamotrigine40$15,582
Clobazam138$8,373
LyricaPregabalin12$7,192
DilantinPhenytoin Sodium Extended16$3,775
Carbamazepine ErCarbamazepine28$3,487
Levetiracetam104$2,905
Oxcarbazepine43$2,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$346$86,34763 claims
Eisai Inc.Fycompa$46,050$56,52748 claims
Sunovion Pharmaceuticals Inc.Aptiom$36,155$45,09025 claims
SK Life Science, Inc.Xcopri$120$24,40319 claims
PfizerLyrica, Dilantin$3,276$10,96628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →